DOCSLIB.ORG

Induced Hypotension During Anesthesia, With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Induced Hypotension During Anesthesia, With Induced Hypotension During Anesthesia, with Special Reference to Orthognathic Surgery Chandra Rodrigo, MBBS, FRCA, FFARCSl, FHKAM (Anaesthesiology) Anaesthetic Unit, Department of Oral and Maxillofacial Surgery, University of Hong Kong, Hong Kong Since Gardner first used arteriotomy during Orthognathic surgery involves the surgical correction anesthesia to improve visibility in the surgical of oral and facial deformities involving bones and field, various techniques and pharmacological soft tissues. There is significant bleeding from both incised agents have been tried for the same purpose. soft tissues and bones during these procedures due to the With reports documenting the spread of acquired rich blood supply to the areas involved. Considerable immune deficiency syndrome through blood bleeding from the bone occurs because most of the ves- transfusions, prevention of homologous blood sels traversing the bones cannot be identified and isolated transfusions during surgery has also become a before or after osseous sectioning. In addition, severe major concern. Induced hypotension has been bleeding may occur during maxillary osteotomies from used to reduce blood loss and thereby address damage to the descending palatine artery, sphenopala- both issues. In orthognathic surgery, induced tine artery, pterygoid venous plexus, or occasionally from hypotension during anesthesia has been used for damage to the second part of the maxillary artery. Severe similar reasons. It is recommended that bleeding can also occur during mandibular osteotomies hypotensive anesthesia be adjusted in relation to from damage to the masseteric artery, retromandibular the patient's preoperative blood pressure rather vein, pterygoid venous plexus, or occasionally from dam- than to a specific target pressure and be limited to age to the facial artery. Furthermore, due to limited ac- that level necessary to reduce bleeding in the cess, poor visibility to isolate and ligate or cauterize ves- surgical field and in duration to that part of the sels that otherwise would have been ligated or cauterized surgical procedure deemed to benefit by it. A with ease adds to the problem of bleeding during orthog- mean arterial blood pressure (MAP) 30% below a nathic surgery, frequently obscuring the operative field. patient's usual MAP, with a minimum MAP of 50 In order to help the surgeon reduce bleeding and to mm Hg in ASA Class I patients and a MAP not improve visibility in the operative field, many anesthetists less than 80 mm Hg in the elderly, is suggested have employed induced hypotension during orthog- to be clinically acceptable. Various nathic surgery. Induced (or controlled) hypotension is a pharmacological agents have been used for method by which the arterial pressure is decreased in a induced hypotension during orthognathic surgery. predictable and deliberate manner. Unlike in procedures In addition, there are many drugs that have been such as aortic surgery, where hypotensive anesthesia is used in other types of surgery that could be used often employed and where the bleeding vessel can often in orthognathic surgery to induce hypotension. be identified, in orthognathic surgery bleeding vessels Recent reports using control groups do not show may not be identified. Although it is similar to lumbar significant differences in morbidity and mortality surgery in this respect, orthognathic surgery differs from attributable to induced hypotension during the latter in that large areas of medullary bone are ex- anesthesia. Appropriate patient evaluation and posed during orthognathic surgery, which contributes to selection, proper positioning and monitoring, and the blood loss. Patients who undergo aortic and lumbar adequate fluid therapy are stressed as important surgery are often old and medically compromised, considerations in patients undergoing induced whereas patients who receive orthognathic surgery are hypotension during orthognathic surgery. usually young and healthy. Thus, the risks of hypotensive anesthesia in orthognathic surgery are far less than in aortic or lumbar surgery. Several controlled'- and uncontrolled studies5 have demonstrated that induced hypotension improves the Received April 14, 1994; accepted for publication May 1, 1995. quality of the surgical field in orthognathic surgery. One Address correspondence to Dr. Chandra Rodrigo, Block 1 Flat A 8, study, by Fromme et al,6 disputes this finding. In this 23 Sha Wan Drive, Pokfulam, Hong Kong. study, though the assessment was by surgeons who were Anesth Prog 42:41-58 1995 ISSN 0003-3006/95/$9.50 © 1995 by the American Dental Society of Anesthesiology SSDI 0003-3006(95)00044-5 41 42 Induced Hypotension Anesth Prog 42:41-58 1995 blind to the method of anesthesia, the comparison was of other ganglionic blocking drugs: hexamethonium,16 tri- operations on both maxillas and mandibles. The specific methaphan,17 and pentolinium.18 Enderby stressed the operations were not stated. The degree of blood loss importance of posture to induce hypotension.15 Subse- during different maxillary and mandibular osteotomies quently, deep anesthesia with volatile inhalational agents may differ. Furthermore, the frequency or the time of became favored by many.19-22 In 1962, Moraca23 first assessment, which may influence the outcome, was not described the use of sodium nitroprusside to induce hy- stated. In a study conducted on patients undergoing spe- potension during anesthesia. Use of cardiac pacemakers cific operations of the maxilla and mandible, where as- to effect hypotension was introduced by Dimant in sessments were carried out at frequent intervals by a sim- 1967.24 Since then, nitroglycerin,25 calcium-channel ilar blind method, there was a significant improvement of blocking agents,26'27 short-acting 0-adrenergic blockers,3 the quality of the surgical field.4 A newer technique of purine compounds,28'29 and prostaglandin El30'3' have estimation of reduced blood loss during orthognathic sur- also been used. gery has been reported in which quantification of blood The first use of hypotensive anesthesia with ganglionic flow to oral tissues in humans is measured using the blocking drugs in maxillofacial surgery was described by Doppler technique.7 In a controlled sLudy using this tech- Enderby.32 The first study on blood loss and hypotensive nique of quantification of blood flow to the maxillary gin- anesthesia in orofacial corrective surgery using sodium gival mucosa, a significant reduction in blood flow follow- nitroprusside was reported by Schaberg in 1976.5 Since ing hypotensive anesthesia was found.8 then, induced hypotension during orthognathic surgery Initially, induced hypotension was also thought to de- using nitroglycerin,'0 labetalol,1" isoflurane,2 and es- crease the surgical time due to improved visibility. Results molol3 has been reported. of controlled studies" 24 indicate that this belief is not true. In many controlledl-4 and uncontrolled studies5'9-1 PHYSIOLOGY where induced hypotension had been employed, blood loss has been less than without hypotensive anesthesia. In order to use induced hypotension for the optimal ben- Again, no statistically significant difference was observed efit of the patient, it is necessary to have an understand- by Fromme et al.6 However, their result may have arisen ing of the regulation of blood flow of vital organs. Even simply because their groups were small numerically. The relatively short periods of unwanted hypotension, such as data in the groups where hypotension was employed, in those associated with "shock," may be followed by irre- fact, showed a trend toward reduced blood loss. versible organ damage. In this situation, the severe de- The recent concern about hazards associated with crease in organ blood flow is accompanied by acid-base blood transfusions, such as transmission of diseases like and metabolic changes. Controlled hypotension rarely acquired immune deficiency syndrome and hepatitis, and results in damage, however, because organ blood flow is the possibility of incompatibility, have increased the de- normally well maintained. mand for techniques to prevent blood loss during surgery Richly perfused tissues, such as the brain, heart, liver, and thereby blood transfusions. In many studies in or- and kidneys exhibit autoregulation of their own blood thognathic surgery, where induced hypotension was em- supply through mechanisms related to the intrinsic elas- ployed there was either no necessity'0"l or a decreased ticity of the vascular smooth muscle and vasodilator sub- requirement2'9 for blood replacement. stances produced in the metabolically active tissues. That is, they maintain their perfusion over a wide range of pressure changes, and it is only when the pressure de- HISTORY creases to relatively low values that adequate perfusion cannot be maintained. This critical pressure varies from Deliberate hypotension to provide a bloodless field and vessel to vessel, organ to organ, and probably from in- better operative conditions for neurosurgery was first pro- dividual to individual. posed by Harvey Cushing in 1917.12 In 1943, Kohlstaedt and Page13 experimenting with dogs described the use of arterial bleeding to produce hypotension resulting in a Central Nervous System state of shock. In 1946, Gardner14 introduced the con- Normally, cerebral blood flow remains constant over a cept of induced hypotension during anesthesia using ar- mean arterial pressure (MAP) range of 60 to 150 mm teriotomy as the technique to induce hypotension and Hg.33 In
Load more

Recommended publications
  • Standards, Limits and Conditions for Prescribing Dispensing And
    College of Naturopathic Physicians of British Columbia CNPBC Scope of Practice for Naturopathic Physicians: Standards, Limits and Conditions for Prescribing, Dispensing and Compounding Drugs May 27, 2010 (Edited 2021-04-30) Standards, Limits and Conditions Draft Framework ACKNOWLEDGEMENTS: The College of Naturopathic Physicians of British Columbia gratefully acknowledges the College of Registered Nurses of British Columbia (CRNBC) for permission to use material from “Scope of Practice for Nurse Practitioners (Family), Standards, Limits and Conditions”, CRNBC, April 2007; for their pioneering efforts in this area of health regulation and for their generous assistance. The College also wishes to acknowledge the extensive support and collaboration received from the College of Pharmacists of BC (CPBC). Their support and assistance has been invaluable. The CNPBC looks forward to ongoing collaboration with these and other health regulatory Colleges in the implementation of prescriptive authority for naturopathic physicians. 2 CNPBC Standards of Practice CNPBC is responsible under the Health Professions Act for setting standards of practice for its registrants. Scope of Practice Standards Scope of Practice Standards set out standards, limits and conditions related to the scope of practice for naturopathic physicians. (See Appendix A.) 3 Contents Introduction .............................................................................................................. 5 Section A – Prescribing and Dispensing PART l – Standards ................................................................................................
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Discriminative Stimulus Effects of Mecamylamine and Nicotine In
    Pharmacology, Biochemistry and Behavior 179 (2019) 27–33 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms T ⁎ Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon Department of Pharmacodynamics, The University of Florida, Gainesville, FL, USA ABSTRACT Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. Here, we examined pharmacological mechanisms underlying the interoceptive effects (i.e., discriminative stimulus effects) of mecamylamine (5.6 mg/ kg s.c.) and compared the effects of nAChR antagonists in this discrimination assay to their capacity to block a nicotine discriminative stimulus (1.78 mg/kg s.c.) in rhesus monkeys. Central (pempidine) and peripherally restricted nAChR antagonists (pentolinium and chlorisondamine) dose-dependently substituted for the me- camylamine discriminative stimulus in the following rank order potency (pentolinium > pempidine > chlorisondamine > mecamylamine). In contrast, at equi- effective doses based on substitution for mecamylamine, only mecamylamine antagonized the discriminative stimulus effects of nicotine, i.e., pentolinium, chlor- isondamine, and pempidine did not. NMDA receptor antagonists produced dose-dependent substitution for mecamylamine with the following rank order potency (MK-801 > phencyclidine > ketamine). In contrast, behaviorally active doses of smoking cessation aids including nAChR agonists (nicotine, varenicline, and cytisine), the smoking cessation aid and antidepressant bupropion, and the benzodiazepine midazolam did not substitute for the discriminative stimulus effects of mecamylamine. These data suggest that peripheral nAChRs and NMDA receptors may contribute to the interoceptive stimulus effects produced by mecamylamine.
    [Show full text]
  • Naturopathic Physicians Regulation
    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Behavioral Pharmacology of Human Drug Dependence
    Behavioral Pharmacology of Human Drug Dependence U S DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration PROPERTY OF DEPR Behavioral Pharmacology of Human Drug Dependence Editors: Travis Thompson, Ph.D. University of Minnesota Chris E. Johanson, Ph.D. The University of Chicago NIDA Research Monograph 37 July 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National lnstitute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the sales superintendent of Documents, US Government Printing Office Washington, DC 20402 The NIDA Research Monograph series Is prepared by the Division of Research of the National Institute on Drug Abuse Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant origInal research Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community Editorial Advisory Board Avram Goldstein, M.D. Addiciton Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California Son Francisco California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont Massachusetts Helen Nowlis, Ph.D. Office of Drug Education DHHS Washington DC Lee Robins, Ph.D. Washington University School of Medicine St Louis Missouri NIDA Research Monograph series William Pollin, M.D. DIRECTOR, NIDA Marvin Snyder, Ph.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,413,463 B1 Yamamoto Et Al
    USOO6413463B1 (12) United States Patent (10) Patent No.: US 6,413,463 B1 Yamamoto et al. (45) Date of Patent: Jul. 2, 2002 (54) PROCESS FOR PRODUCING HARD (56) References Cited CAPSULE U.S. PATENT DOCUMENTS (75) Inventors: Taizo Yamamoto, Osaka; Shunji 5,264,223. A 11/1993 Yamamoto et al. ......... 424/451 Nagata, Ashiya; Seinosuke Matsuura, 5.431,917. A 7/1995 Yamamoto et al. ......... 424/451 Kyoto, all of (JP) 5,756,123 A 5/1998 Yamamoto et al. ......... 424/451 (73) Assignee: Shionogi Qualicaps Co., Ltd., FOREIGN PATENT DOCUMENTS Yamatokoriyama (JP) EP A1-714656 6/1996 EP B1-592130 4/1999 * ) Notice: Subject to anyy disclaimer, the term of this JP A-58138.458 8/1983 patent is extended or adjusted under 35 JP A-32.79325 12/1991 U.S.C. 154(b) by 0 days. JP A-6116139 4/1994 (21) Appl. No.: 09/582,560 JP A-82O8458 8/1996 (22) PCT Filed: Oct. 25, 1999 Primary Examiner Leo B. Tentoni (74) Attorney, Agent, or Firm-Birch, Stewart, Kolasch & (86) PCT No.: PCT/JP99/05874 Birch, LLP S371 (c)(1), (57) ABSTRACT (2), (4) Date: Jun. 29, 2000 A method of manufacturing hard capsules is characterized (87) PCT Pub. No.: WO00/25760 by comprising the Steps of dispersing a water-Soluble cel lulose derivative in hot water and cooling the dispersion to PCT Pub. Date: May 11, 2000 effect dissolution of the water-soluble cellulose derivative in (30) Foreign Application Priority Data the water, adding and dissolving a gelling agent in the water-Soluble cellulose derivative Solution to give a capsule Oct.
    [Show full text]
  • Drugs Thought to Be Safe in Porphyria
    Drugs Thought To Be Safe in Porphyria Acetazolamide acetylcholine Actinomycin D [6] Acyclovir Adenosine monophosphate Adrenaline Alclofenac Allopurinol Alpha tocopheryl Acetate Amethocaine Amiloride Aminocaproic acid Aminoglycosides Amoxicillin Amphotericin Ampicillin Ascorbic acid Aspirin Atenolol Atropine Azathioprine Beclomethasone Benzhexol HCl Beta-carotene Biguanides [Bromazepam] Bromides Buflomedil HCl Bumetanide Bupivacaine Buprenorphine Buserelin Butacaine SO4 Canthaxanthin Carbimazole [Carpipramine HCl] Chloral hydrate [Chlormethiazole] [Chloroquine] [Chlorothiazide] Chlorpheniramine Chlorpromazine Ciprofloxacin Cisapride Cisplatin Clavulanic acid Clofibrate Clomiphene Cloxacillin Co-codamol Codeine phosphate Colchicine [Corticosteroids] Corticotrophin (adrenocorticotropic hormone [ACTH]) Coumarins Cyclizine Cyclopenthiazide Cyclopropane [Cyproterone acetate] Danthron Desferrioxamine Dexamethasone [Dextromoramide] Dextrose Diamorphine Diazoxide Dicyclomine HCl Diflunisal Digoxin Dihydrocodeine Dimercaprol Dimethicone Dinoprost Diphenoxylate HCl Dipyridamole [Disopyramide] Domperidone Doxorubicin HCl Droperidol [Estazolam] Ethacrynic acid Ethambutol [Ethinyl oestradiol] Ethoheptazine citrate Etoposide Famotidine Fenbufen [Fenofibrate] Fenoprofen Fentanyl Flucytosine Flumazenil Fluoxetine HCl Flurbiprofen Fluvoxamine Maleate Folic acid Fructose Fusidic acid Follicle-stimulating hormone Gentamicin Glafenine Glucagon Glucose Glyceryl trinitrate Goserelin Guanethidine Guanfacine HCl Haem arginate [Haloperidol] Heparin Heptaminol HCl Hexamine
    [Show full text]
  • Nicotinic Ganglion Blockers Are Agents Which Block the Stimulant Actions of Nicotine Or Dimethyl Phenylpiperazinium (DMPP) Or Acetyl Choline at the Ganglia
    ANALYSIS OF MODE OF ACTION OF SOME NICOTINIC BLOCKING DRUGS O.P. SETHI* and O.D. GULATI Pharmacological Research Unit, Council of Scientific and Industrial Research, New Delhi and Department of Pharmacology, Medical College, Baroda, India Accepted December 20, 1972 Abstract-Hexamethonium and tetraethylammonium (TEA) produced parallel shifts (equilibrium blockade) of nicotine and dimethylphenylpiperazinium dose-response curves at all dose levels on isolated rabbit and guinea pig ileum preparations, while mecamylamine, pempidine, chlorisondamine and pentolinium produced parallel shifts at lower doses and nonparallel shifts (nonequilibrium blockade) at higher dose levels. Hexamethonium and TEA protected against the nonequilibrium blockade by mecamylamine, pempidine, chlorisondamine and pentolinium. Dose ratios for the combination of hexamethonium with TEA, with chlorisondamine or with pen tolinium were consistent with competitive type of blockade. Dose ratios for the combination of hexamethonium with mecamylamine or with pempidine were not consistent with the noncompetitive type of blockade. It is concluded, that hexametho nium and TEA act as equilibrium competitive ganglion blockers while mecamylamine, pempidine, chlorisondamine and pentolinium act as nonequilibrium competitive ganglion blockers. Nicotinic ganglion blockers are agents which block the stimulant actions of nicotine or dimethyl phenylpiperazinium (DMPP) or acetyl choline at the ganglia. Chemically, these agents may be divided into two groups. Some of the quaternary onium compounds which comprise the first group include hexamethonium, tetraethylammonium (TEA), chlorisondamine and pentolinium. Mecamylamine and pempidine which are amines fall into the second group. Hexamethonium and TEA block the stimulant actions of nicotine or acetyl choline or DMPP (1-3) on the ganglia competitively. Mecamylamine and pentolinium (4, 5) act in a manner similar to hexamethonium.
    [Show full text]
  • Appendix PSYCHIATRIC SIDE EFFECTS of MEDICAL DRUGS
    Appendix PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS General Classification Generic Trade Name Psychiatric Side Effects Sulfonamides* Mafenide acetate Sulfamylon General statement regarding Phthelylsulfathiazole sulfonamides: Salicylazosulfapyridine depression Sulfacetamide sodium Sultrin Triple Sulfa psychosis Sulfachlorpyridazine restlessness Sulfadiazine Suladyne irritabili ty Sulfamerazine Sulfameter Sulla Sulfamethazine Sulfamethizole Azotrex Micro sui w Microsul-A (1l w Suladyne *May cause retardation if given Thiosulfil during 3rd trimester, to nursing Thiosulfil Forte mothers, or to children less than Thiosulfil-A Forte 2 months old Uro biotic-250 Sulfamethoxazole Azo Gantanol Bactrim DS Bactrim Gantanol Gantanol DS Septra DS Septra Sulfaphenasole Sulfisoxazole Azo Gantrisin Gantrisin SK-Soxazole Sulfisoxazole Vagilia PSYCHIATRIC SIDE EFFECTS OF MEDICAL DRUGS (Cont.) General Classification Generic Trade Name Psychiatric Side Effects Sulfones Dapsone General statement regarding Sulfoxone sodium sulfones: nervousness insomnia psychosis An thelmin tics Aspidium oleoresin Male Fern Oleoresin Delirium Quinacrime HCl Atabrine HCI Psychosis Tetrachloroethylene Inebriation Antitubercular Agents Cycloserine Seromycin Confusion Lethargy (,) Psychosis 0'1 Ethionamide Trecator-SC Depression .... Isoniazid INH Toxic psychosis Isonicotinic Acid Hydrazine Parasthesia Hyzyd Excitement Laniazid Euphoria Niconyl Nydrazid Teebaconin Rifampin Rifadin Confusion Rimactane Antimalarials Chloroquine HCI Aralen
    [Show full text]
  • (1: 2: 2: 6: 6-Pentamethylpiperidine), A
    Brit. J. Pharmacol. (1958), 13, 339. PHARMACOLOGICAL PROPERTIES OF PEMPIDINE (1: 2: 2: 6: 6 - PENTAMETHYLPIPERIDINE), A NEW GANGLION - BLOCKING COMPOUND BY S. J. CORNE AND N. D. EDGE From the Research Laboratories, May & Baker Ltd., Dagenham, Essex * (RECEIVED JuNE 27, 1958) Pempidine (1: 2: 2: 6: 6-pentamethylpiperidine) is a long-acting ganglion-blocking compound which is effective by mouth. By intravenous injection it has a similar potency to hexamethonium on the preganglionically stimulated nictitating membrane of the cat. The compound blocks the effects of intravenous nicotine and of peripheral vagal stimulation on the blood pressure; it also causes dilatation of the pupil after removal of the sympathetic innervation. On the guinea-pig ileum, the predominant effect of the compound is to inhibit nicotine contractions. Pempidine is well absorbed from the gastro-intestinal tract as judged by (a) the low ratio (6.9) of oral to intravenous toxicities, (b) the rapid development of mydriasis in mice after oral administration of small doses, and (c) the rapid onset of hypotension when the compound is injected directly into the duodenum of anaesthetized cats. Other actions include neuromuscular paralysis of curare-like type when large doses of the compound are injected intravenously and central effects such as tremors which occur with near toxic doses. In cats with a low blood pressure, large intravenous doses have a slight pressor action. Until recently ganglion-blocking compounds of has been described independently by Spinks and high potency and specificity were thought to Young (1958). be confined to polymethylene bis-quaternary METHODS ammonium series, such as hexamethonium (Paton Cats were anaesthetized with ether or thiopentone, and Zaimis, 1951) and pentolinium (Mason and which was followed by chloralose (80 mg./kg.).
    [Show full text]